Progestins Activate the AKT Pathway in Leiomyoma Cells and Promote Survival
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
CONTEXT: Progesterone has been associated with promoting growth of uterine leiomyomas. The mechanisms involved remain unclear. OBJECTIVE: In this study we investigated the activation of the AKT pathway and its downstream effectors, glycogen synthase kinase-3b and Forkhead box O (FOXO)-1 by progesterone as a mechanism of proliferation and survival of leiomyoma cells. Inhibitors of the AKT pathway were used to demonstrate the role of phosphatidylinositol 3-kinase, AKT, and FOXO1 in contributing to cell proliferation and apoptosis. RESULTS: Treatment of leiomyoma cells with R5020 over a period of 72 h resulted in higher cell numbers compared with untreated cells. When cells were treated with 100 nm R5020 for 1 and 24 h, the levels of phospho(Ser 473)-AKT increased. This increase was inhibited when cells were cotreated with RU486. Treatment of leiomyoma cells with a phosphatidylinositol 3-kinase inhibitor, LY294 dramatically decreased levels of phospho(Ser 473)-AKT, despite R5020 treatment. In addition to increased phospho(Ser 473)-AKT levels, R5020 treatment resulted in an increase in phospho(Ser 256)-FOXO1 and phosphoglycogen synthase kinase-3b. Inhibition of AKT using API-59 decreased proliferation and cell viability even in the presence of R5020. Higher concentrations of API-59-induced apoptosis of leiomyoma cells, even in the presence of R5020. Psammaplysene A increased nuclear FOXO1 levels and did not affect cell proliferation but induced apoptosis of leiomyoma cells. CONCLUSIONS: The progestin, R5020, can rapidly activate the AKT pathway. Inhibition of the AKT pathway inhibits cell proliferation and promotes apoptosis of leiomyoma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aromatase in endometriosis and uterine leiomyomata
Bulun, S. E., Imir, G., Utsunomiya, H., Thung, S., Gurates, B., Tamura, M., & Lin, Z. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.04.012 · Cited by 154 · cited 3×
“BrdU was then detected by an immunoassay according to the manufacturer’s protocol (Roche Applied Sciences, Indianapolis, IN) and the reaction J Clin Endocrinol Metab, May 2009, 94(5):1768–1774 jcem.”
BackgroundMethodInfluentialSelf-citation
Cited by
Bulun, S. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1209993 · Cited by 703
Self-citationUlipristal Acetate versus Leuprolide Acetate for Uterine Fibroids
Donnez, J., Tomaszewski, J., Vázquez, F., Bouchard, P., Lemieszczuk, B., Baró, F., Nouri, K., Selvaggi, L., Sodowski, K., Bestel, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103180 · Cited by 607
Stewart, E. A., Laughlin-Tommaso, S. K., Catherino, W. H., Lalitkumar, S., Gupta, D., & Vollenhoven, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.43 · Cited by 531
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Self-citationRole of nuclear progesterone receptor isoforms in uterine pathophysiology
Patel, B., Elguero, S., Thakore, S., Dahoud, W., Bedaiwy, M., & Mesiano, S. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu056 · Cited by 353
Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics
Islam, M. S., Ciavattini, A., Petraglia, F., Castellucci, M., & Ciarmela, P. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx032 · Cited by 321
Segars, J. H., Parrott, E. C., Nagel, J. D., Guo, X. C., Gao, X., Birnbaum, L. S., Pinn, V. W., & Dixon, D. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt058 · Cited by 186
“Cell numbers (+) Progestin/cultured uterine Phospho(Ser 256)-FOXO1, (Hoekstra et al., 2009) leiomyoma cells (Hoekstra phosphoglycogen synthase kinase-3b, et al.”
BackgroundThe role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy
Tal, R., & Segars, J. H. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt042 · Cited by 159
“In addition, others have reported increased levels of pAKT in leiomyomas compared with normal myometrial cells (Kovacs et al., 2007; Hoekstra et al., 2009).”
BackgroundSignaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy
Borahay, M. A., Al-Hendy, A., Kilic, G. S., & Boehning, D. (2015) · Molecular Medicine · doi:10.2119/molmed.2014.00053 · Cited by 158
Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
“Mifepristone-induced fibroid regression is partly mediated by the alteration of cell growth and the suppression of TGF-β activity (272), AKT levels (116), as well as expression of proliferating cell nuclear antigen (PCNA) and the antiapoptotic protein Bcl-2 (273).”
BackgroundTherapeutic Roles of Statins in Gynecology and Obstetrics: The Current Evidence
Zeybek, B., Costantine, M., Kilic, G. S., & Borahay, M. A. (2018) · Reproductive Sciences · doi:10.1177/1933719117750751 · Cited by 31
“Uterine fibroids are the most common tumors of female reproductive tract with a lifetime incidence of 50% to 70%.(23) Although treatment options exist such as contraceptive steroids, gonadotropin-releasing agonists, progesterone modulators, uterine artery embolization, and radiofrequency ablation, they mostly provide…”
Background
Metadata
- Authors
- Hoekstra, A. V., Sefton, E. C., Berry, E., Lu, Z., Hardt, J., Marsh, E., Yin, P., Clardy, J., Chakravarti, D., Bulun, S., & Kim, J. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-05-01
- Volume
- 94
- Issue
- 5
- Pages
- 1768-1774
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2016434268
- Cited by
- 93
- References
- 1
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.